Last edition
News about "zenagamtide"
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
Zenagamtide | 08/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members